VivoSeq
Infectious Disease

HPV Vaccine

0

Pipeline Programs↗

8

Active Trials↗

3

Companies Involved↗

HPV Vaccine is an early-stage landscape with 0 programs across 3 companies. The most active players are Merck & Co., GSK, Beijing Health Guard Biotechnology, Inc.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

88/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalB

Beijing Health Guard Biotechnology, Inc

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

25

clinical trials

Completed14 · 56%
Recruiting5 · 20%
Active, not recruiting3 · 12%
Unknown status1 · 4%
Withdrawn1 · 4%
Terminated1 · 4%

Clinical Trials

Trial Activity

25 trials

A Study of Reduced Dosing of the Nonavalent HPV Vaccine in Women Living With HIV
Recruiting·UUniversity of British Columbia·Phase 4·NCT05495906·275 enrolled
HPV Vaccine, Imiquimod, and Metformin Combination Trial
Recruiting·—·Phase 2·NCT06686043·85 enrolled
HPV Vaccine Reduced Dose
Recruiting·EEmory University·Phase 4·NCT06799494·100 enrolled
Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts
Recruiting·ZZagazig University·Phase 2·NCT05291845·162 enrolled
PANHPVAX, Study of a New HPV Vaccine in Healthy Volunteers
Recruiting·GGerman Cancer Research Center·Phase 1·NCT05208710·45 enrolled
A Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian Girls
Active, not recruiting·LLondon School of Hygiene and Tropical Medicine·Phase 3·NCT02834637·930 enrolled
An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old
Active, not recruiting·XXiamen University·Phase 3·NCT05056402·1,382 enrolled
Intradermal, Fractional Dose of HPV Vaccines:
Active, not recruiting·UUniversity of Washington·Phase 4·NCT04235257·40 enrolled
Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002)
Completed·Merck & Co. logoMerck & Co.·Phase 1·NCT00851643·158 enrolled
Alternate Dosing Schedules Study for HPV Vaccine (ADS)
Completed·—·N/A·NCT02280642·331 enrolled
Broad Spectrum HPV Vaccine Dose Ranging Study (V502-001)
Completed·Merck & Co. logoMerck & Co.·Phase 2·NCT00260039·680 enrolled
A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine
Completed·BBeijing Health Guard Biotechnology, Inc·Phase 1·NCT05680454·160 enrolled
HPV Vaccine Immunity in High-risk Women
Completed·MMurdoch Childrens Research Institute·Phase 4·NCT04590521·63 enrolled
Study to Test the Safety of HPV Vaccine in Women (V501-011)(COMPLETED)
Completed·Merck & Co. logoMerck & Co.·Phase 3·NCT00517309·1,877 enrolled
Preparedness Study - HPV Vaccine
Completed·HH. Lee Moffitt Cancer Center and Research Institute·N/A·NCT01489527·406 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)